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Introduction
Staphylococcus aureus is a leading cause of serious sys-
temic infections (e.g., endocarditis, pneumonia, ab-
scesses, septicemia, and osteomyelitis) and often
requires hospitalization and intensive antimicrobial
therapy (1). The emergence of S. aureus resistance to
multiple antibiotics, including semisynthetic peni-
cillins, quinolones, and vancomycin, has hastened the
need to design more effective antimicrobial regimens
(2). Consequently, novel strategies for the therapy of
such infections have been sought, including the tar-
geting of known staphylococcal virulence factors for
attenuation (3, 4). Delineating compounds that sup-
press structural or regulatory staphylococcal genes
crucial for pathogenesis would potentially accomplish
two goals: (a) enhancement of the efficacy of tradi-
tional antimicrobial therapy, and (b) reduction in the
selective pressure that drives antibiotic resistance (5).
Salicylic acid, the major in vivo metabolite of
aspirin, has been demonstrated to interfere with vir-
ulence factors at a transcriptional level in several
viruses, including the respiratory syncytial virus and
HIV-1. Furthermore, in mammalian and plant cells,
this compound has been reported to impact intracel-
lular signaling processes and the cytokine network (6,
7). We recently showed that treatment of an invasive
experimental S. aureus infection (endocarditis) with
intravenous aspirin caused a significant reduction in
bacterial densities within target tissues (vegetations
and kidneys), and that these effects are mediated by
salicylic acid (8). We reasoned that salicylic acid may
exert a direct effect on bacterial adhesins that are nec-
essary for bacterial colonization and propagation in
host tissues, or on staphylococcal global regulatory
elements such as the staphylococcal accessory regu-
lator, sarA, and the accessory gene regulator, agr.
These two loci also coregulate genes that encode a
variety of exoenzymes and exotoxins, including
those responsible for cytolysis of host tissues (e.g.,
the α-hemolysin gene, hla) (9, 10).
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In this study, we demonstrate that the observed
antivirulence properties of aspirin in vivo are based on
the direct antimicrobial effects of its metabolite, sali-
cylic acid, and involve activation of the stress-induced
transcription factor sigB, leading to repression of the
sarA and agr global regulons in S. aureus.
Methods
Bacterial strains, plasmids, and growth media. The bacterial
strains and plasmids used in this study are listed in
Table 1. These strains were selected to represent a broad
range of methicillin-susceptible and methicillin-resist-
ant phenotypes, as well as both clinical and laboratory-
derived constructs. All the clinical strains were isolated
from patients with serious human infections requiring
hospitalization, such as wound infections and endo-
carditis. Erythromycin (5 µg/ml) and chloramphenicol
(10 µg/ml) were used for selection of transformants
and transductants in S. aureus, as indicated. Prior to in
vitro experiments, S. aureus strains were grown at 37°C
in plain tryptic soy broth (control cells) or in medium
containing 30 or 50 µg/ml salicylic acid for 18 hours to
the late postexponential phase on a rotary shaker.
These salicylic acid concentrations encompass readily
achievable serum levels observed during therapy of
experimental S. aureus endocarditis (11). No impact of
salicylic acid on the 24-hour S. aureus growth kinetics
was observed at these concentrations (data not shown).
In addition, the pH of the bacteria–salicylic acid reac-
tion mixtures did not change as a result of either final
concentration of salicylic acid used.
Impact of salicylic acid on S. aureus adherence to fibrinogen
and fibronectin. The fibrinogen- and fibronectin-bind-
ing capacities of S. aureus strains were evaluated by
direct binding of washed bacterial cells (5 × 103 CFUs)
to solid-phase fibrinogen and fibronectin in six-well
plates (9, 10). Plates were coated with 50 µg/ml fib-
rinogen or fibronectin (Sigma Chemical Co., St. Louis,
Missouri, USA), incubated at room temperature for 24
hours, washed three times with PBS, blocked with
blocking solution, and washed three more times. Bac-
terial cells (5 × 103 CFUs) were applied to individual
wells and incubated for 1 hour at 37°C on a rotating
platform. After removal of unbound cells by washing
three times with PBS, 2 ml of tryptic soy agar was over-
lain in all wells. After 24 hours of incubation at 37°C,
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Table 1
Bacterial strains and plasmids used in this study
Strain or plasmid Comment Reference
S. aureus
RN6390 Laboratory strain related to 8325-4, harboring an 11-bp deletion in rsbU 45
ALC1001 sigB mutant of RN6390 28
ALC1497 Complemented sigB mutant of RN6390 28
SH1000 Functional rsbU derivative of 8325-4, rsbU+ 17
ALC2732 sarA mutant of SH1000 This study
ALC1435 RN6390 with pALC1420 (gfpuvr with sarA P1 promoter) 22
ALC1437 RN6390 with pALC1421 (gfpuvr with sarA P2 promoter) 22
ALC1436 RN6390 with pALC1422 (gfpuvr with sarA P3 promoter) 22
ALC2200 RN6390 with asp23 promoter driving gfpuvr in pSK236 24
ALC2770 SH1000 with asp23 promoter driving gfpuvr in pSK236 24
ALC1540 RN6390 with sarA P3-P1-P2 promoter driving gfpuvr in pSK236 22
ALC1740 gfpuvr with hla promoter in pSK236 in RN6390 This study
ALC1747 gfpuvr with fnbA promoter in pSK236 in RN6390 This study
ALC1737 gfpuvr with fnbB promoter in pSK236 in RN6390 This study
ALC1741 gfpuvr with spa promoter in pSK236 in RN6390 This study
ALC1742 gfpuvr with agr RNAII promoter in pSK236 in RN6390 This study
ALC1743 gfpuvr with agr RNAIII promoter in pSK236 in RN6390 This study
ALC136 sarA mutant of RN6390 48
ALC2322 FDA486 with asp23 promoter driving gfpuvr in pSK236 This study
COL Methicillin-resistant laboratory strain 49
RUSA168 sigB mutant of COL 49
ISP479C Spontaneous plasmid-cured derivative of parental strain ISP479 50
6850 Clinically isolated wild-type strain 51
Newman Laboratory strain 52
MRSA 67-0 Wound isolate 53
Duke strains 28, 153, 237 Isolates from patients with infective endocarditis 54
Plasmids
pSK236 Shuttle vector containing pUC19 cloned into the HindIII site of pC194 52
pALC1420 pSK236 containing gfpuvr preceded by the 240-bp sarA P1 promoter fragment 17
pALC1421 pSK236 containing gfpuvr preceded by the 162-bp sarA P3 promoter fragment 17
pALC1422 pSK236 containing gfpuvr preceded by the 382-bp sarA P2 promoter fragment 17
visible colonies were counted. As the binding patterns
of the clinical and laboratory isolates were virtually
identical, data were pooled within each isolate group,
and bacterial binding was quantified as the percentage
of the initial inoculum bound; the impact of salicylic
acid exposure on binding was expressed as the mean
reduction (± SD) of fibrinogen or fibronectin binding
when compared with that of control cells unexposed to
salicylic acid, from six separate runs.
Bacterial cells were pre-exposed to 6 mM sodium azide
for 60 minutes at room temperature after overnight cul-
ture in the absence and presence of salicylic acid; then
binding experiments were repeated to ascertain the
requirement for an energy-dependent process.
To evaluate whether the effects of salicylic acid on S.
aureus binding to fibrinogen and fibronectin are medi-
ated via the upregulation of a serine protease (which
cleaves and degrades such adhesins), we performed the
fibronectin-binding experiments in parallel with cul-
tures pre-exposed to 0.4 U of the global protease
inhibitor α2-macroglobulin (12).
The sarA operon positively regulates the expression of
a number of adhesin genes (13, 14), while the global
stress regulon sigB negatively regulates the function of
several adhesin genes (via repression of sarA gene
expression; refs. 15, 16). To determine whether sigB is
involved in salicylic acid–mediated effects on S. aureus
binding to fibrinogen and fibronectin, we evaluated
fibrinogen and fibronectin binding in vitro in the fol-
lowing constructs: parental strain COL; its respective
sigB deletion mutant; parental strain RN6390; its
respective sigB deletion mutant; and its sigB-comple-
mented strain. To explore the role of rsbU within the
sigB operon, we also compared the salicylic acid–medi-
ated effects on adhesin binding of RN6390, which car-
ries a natural rsbU deletion, with those of SH1000, a
derivative of RN6390 that carries a functional rsbU
gene (17). To determine whether the sarA operon is
involved in S. aureus binding to the above adhesion
molecules, salicylic acid–mediated effects on S. aureus
binding to fibrinogen and fibronectin were evaluated
in sarA knockout mutants of RN6390 and SH1000.
Impact of salicylic acid on hemolytic and thrombolytic (platelet
lysis) activity of S. aureus. In addition to matrix protein
binding, the secretion of exotoxins, such as α-hemolysin,
represents a major virulence factor in staphylococcal
pathogenesis by virtue of its cytolytic effect on many
types of host cells (18). We thus evaluated whether sali-
cylic acid would impact α-hemolysin activity in S. aureus,
using two distinct target cells for this enzyme, rabbit ery-
throcytes and rabbit platelets.
For hemolytic studies, cells in each tube were
washed, equalized at OD600, and centrifuged at 5,000
g for 10 minutes to pellet bacteria. Aliquots of serial
dilutions of culture supernatants were added to a 1%
suspension of washed rabbit erythrocytes in 0.01 M
PBS (pH 7.2) containing 0.1% BSA (19). Purified α-hemo-
lysin (1 µg/ml; kindly provided by Barbara E. Menzies,
Vanderbilt University, Nashville, Tennessee, USA) was
used as a positive control. Since supernatants of both
the parental clinical and laboratory S. aureus strains
yielded virtually identical hemolytic activity, pooled
data for each isolate group were expressed as mean
units of hemolytic activity (± SD) of all parental
strains per milliliter of culture supernatant from six
separate runs. The hemolytic units were defined as the
reciprocal of the highest dilution of the culture super-
natant that caused 50% hemolysis as measured by
optical densitometry (19).
For the thrombolytic studies, washed platelets were
suspended in Tyrode’s medium and adjusted to an
OD600 of 1.0 (equal to approximately 109 platelets/ml).
Platelets were then exposed to serial dilutions of cul-
ture supernatants. Thrombolysis was monitored by
measurement of the fall in OD600 over 30 minutes (19).
Purified α-hemolysin and the membrane detergent Tri-
ton X-100 (0.1%) were used as positive thrombolysis
controls. Exposure of rabbit platelets to Triton X-100
or purified α-hemolysin resulted in 100% lysis (i.e.,
decrease in the OD600 of the platelet suspension from
1.0 to base line) within 30 minutes. Thrombolytic activ-
ity was expressed as the mean fall of OD600 (± SD) as
normalized to Triton X-100 from six separate runs.
Impact of salicylic acid on α-hemolysin production. As a
complement to the above functional assays for α-hemo-
lysin, we studied the impact of salicylic acid on the
specific production of this toxin. Culture super-
natants from equal numbers of S. aureus parental
cells Newman and RN6390, and the relevant sigB
deletion and sigB-complemented variants, precul-
tured in the absence or presence of salicylic acid, were
diluted and applied to a 12% SDS-polyacrylamide gel
for α-hemolysin detection by immunoblot. The gel
proteins were electrophoretically transferred to nitro-
cellulose membranes. After the membranes were blot-
ted, they were blocked with 0.5% Tween-20 in Tris-
buffered saline, and then incubated for 1 hour with
rabbit polyclonal anti–α-hemolysin serum (1:100
dilution). The blot was developed with goat anti-rab-
bit IgG–alkaline phosphatase conjugate (Molecular
Probes Inc., Eugene, Oregon, USA) at a 1:2,000 dilu-
tion using nitroblue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate as the substrate (20).
Impact of salicylic acid on protease and lipase production.
We evaluated the effects of salicylic acid on lipase and
protease secretion, two sarA-repressible phenotypes, by
spectrophotometric assays in postexponential culture
supernatants of the parental study strains, Newman,
RN6390, COL, and ISP479C, as well as in the sigB
mutant and sigB-complemented variant of RN6390, in
the presence or absence of salicylic acid (50 µg/ml).
For quantification of global protease activity, the
azocasein spectrophotometric hydrolysis assay was
used. After equalizing all cultures at OD600, 300 µl of
culture supernatants were added to 800 µl of an azo-
casein solution and incubated for 16 hours at 37°C.
Undegraded azocasein was precipitated by the addi-
tion of 400 µl of 50% trichloroacetic acid and removed
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by centrifugation. Protease activity was indicated by
clearing of the supernatant solution with a concomi-
tant decrease in OD340 (21).
For quantification of lipase activity, a tributyrin assay
was used, as previously described (21). In brief, 1 ml of
the prewarmed tributyrin emulsion (50°C) was added
to 100 µl of each standardized culture supernatant. The
OD was monitored at 450 nm at room temperature.
Lipase activity was indicated by a clearing of the emul-
sion and quantified by a subsequent decrease in OD.
As the protease and lipase activities of parental S.
aureus cells were virtually identical, data were pooled,
and the impact of salicylic acid was expressed as the
result of six separate runs based on the normalized OD
of cells grown in the absence of salicylic acid.
Whole-cell ELISA for detection of cell wall–associated pro-
tein A. To determine levels of protein A production (a
sarA-repressible phenotype), cell wall–associated pro-
teins were extracted from overnight cultures of strain
Newman and of strain RN6390, its sigB mutant, and
its sigB-complemented strain, using lysostaphin in a
hypertonic medium (30% raffinose). Microtiter wells
were coated with human IgG at 1 µg/ml overnight at
37°C. Serial dilutions of extracts of cell wall proteins
in 1× PBS, 0.05% Tween-20, and a control protein A
standard (Calbiochem Corp., San Diego, California,
USA) were added to microtiter wells, then probed with
affinity-purified chicken anti–protein A antibody (Ac-
curate Chemical & Scientific Group., Westbury, New
York, USA) at a 1:3,000 dilution. Bound antibody was
detected by immune colorimetry with rabbit anti-
chicken IgG (1:5,000 dilution) conjugated to alkaline
phosphatase (Jackson ImmunoResearch Laboratories
Inc., West Grove, Pennsylvania, USA), using p-nitro-
phenyl phosphate as a developing substrate. Microtiter
wells were then read in an ELISA plate reader (Bio-Tek
Instruments Inc., Winooski, Vermont, USA) and ex-
pressed as the average of two runs.
Impact of salicylic acid on promoter gene expression in vitro
and in vivo. To define whether salicylic acid–induced
changes in S. aureus binding to matrix proteins, and 
α-hemolysin production, were attributable to impacts
on virulence gene expression, we employed a gene
reporter system. We used a shuttle plasmid with a pro-
moterless, modified GFP reporter gene (gfpuvr) that has
been optimized for use in fluorometry and flow cytom-
etry analyses (22, 23). The following promoters relevant
to the present study were cloned upstream of the gfpuvr
reporter gene in strains RN6390, SH1000, and FDA486
to assay the impact of salicylic acid as previously
detailed (23): fnbA and fnbB promoters (the two major
fibronectin protein-binding genes); hla promoter; spa
promoter; individual sarA P1 and sarA P3 promoters;
sarA P2-P3-P1 promoter; agr RNAII and RNAIII pro-
moters; and asp23 promoter (a sigB-dependent locus,
and a surrogate for sigB promoter activation; ref. 24).
The GFP excitation maximum in these constructs has
been shifted from 395 to 488 nm by a single substitu-
tion at residue 65 (serine to threonine [S65T]), yielding
GFPuvr (22, 23). GFP fluorescence was detected by exci-
tation at 488 nm and emission at 520 nm. Fluorome-
try (Turner Fluorometer model 450; Barnstead Inter-
national, Dubuque, Iowa, USA) or flow cytometry
(FACSCalibur; Becton Dickinson Biosciences, Sparks,
Maryland, USA) was conducted on equal concentra-
tions of bacterial cells to quantitate in vitro expression
of GFP. Results were expressed as the average of three
separate runs. Fluorescence microscopy (Olympus
America Inc., Melville, New York, USA) was used to de-
tect the impact of acetylsalicylic acid or salicylic acid on
in vivo expression of GFP in cells within vegetative
lesions removed from rabbits with infective endocardi-
tis (22). The slides were also stained with Giemsa stain
for localization of bacteria within the vegetations. In
addition, to provide a more quantitative assessment of
in vivo gene expression, 10,000 intravegetation sta-
phylococcal cells from control or aspirin-treated rab-
bits were evaluated for sarA P1 GFP fluorescence by
flow cytometry as previously described (25).
Impact of salicylic acid on sarA gene transcription by North-
ern analysis. For staphylococcal RNA extraction, 10-ml
cultures of S. aureus RN6390 and Newman were grown
to mid–log phase (OD650, 0.7), late log phase (OD650,
1.1), and postexponential phase (OD650, 1.7), pelleted by
centrifugation, resuspended in FastRNA reagent (Qbio-
gene Inc., Carlsbad, California, USA) in combination
with 0.1-mm Zirconia-silica beads, and shaken at 6,000
rpm in a high-speed homogenizer for 20 seconds. After
addition of 200 µl chloroform, the sample was centri-
fuged at 12,000 g at 4°C for 10 minutes. The RNA locat-
ed in the upper aqueous layer was precipitated with iso-
propanol and resuspended in water treated with Diethyl
pyrocarbonate. The integrity of the RNA species was
verified with a formaldehyde gel (26). Ten micrograms
of RNA from each culture condition was electro-
phoresed through a 1.5% agarose, 0.66 M formaldehyde
gel in Mops running buffer (26). RNA was blotted onto
Hybond N+ membranes (Amersham Biosciences Corp.,
Piscataway, New Jersey, USA) using a TurboBlotter alka-
line transfer system (Schleicher & Schuell Inc., Keene,
New Hampshire, USA). For detection of sarA tran-
scripts, gel-purified DNA probes were radiolabeled with
[α-32P]dCTP by the random-primer method, and
hybridized under high-stringency conditions. The blots
were subsequently washed and autoradiographed (27).
Impact of salicylic acid on SarA protein production. S. aureus
strain SH1000, carrying an intact sigB operon, was dilut-
ed 1:100 from an overnight culture into 50 ml of tryp-
tic soy broth containing 50 µg/ml of salicylic acid; the
control culture did not contain any salicylic acid. Both
cultures grew to similar OD and were harvested 8 hours
later (the time of maximal SarA protein expression).
Cell-free extracts of each culture were prepared as
described (28). The protein concentration of each prepa-
ration was determined by the Bradford assay (Bio-Rad
Laboratories Inc., Hercules, California, USA). Equivalent
amounts of cell-free extract of each cell preparation were
then loaded onto a 12% SDS gel, resolved, and blotted
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onto nitrocellulose. The blot was then incubated with
blocking buffer, probed with an anti-SarA murine mAb
(1:1,000 dilution) followed by a sheep anti-mouse–alka-
line phosphatase conjugate (1:5,000 dilution) (Jackson
ImmunoResearch Laboratories Inc.), and then devel-
oped as previously described (28). Band intensities were
then quantitated by densitometry using SigmaGel soft-
ware (SPSS Inc., Chicago, Illinois, USA) and expressed
as the average of two separate experiments.
Rabbit endocarditis model. To evaluate the in vivo role of
the sarA and the sigB operons in mediating the antimi-
crobial effects of salicylic acid, we induced endocarditis
in rabbits with the parental strain RN6390 and its rsbU-
repaired derivative SH1000; the parental strain COL;
the respective sigB and sarA mutants; and the sigB-com-
plemented variant of RN6390. In brief, anesthetized
rabbits (New Zealand white; Irish Farms, Corona, Cali-
fornia, USA) underwent transcarotid-transaortic valve
catheterization with a polyethylene catheter to induce
sterile aortic valve vegetations. The catheter remained
indwelling for the duration of this study. Animals were
challenged intravenously with the ID95 inoculum of the
study S. aureus strains (as established by pilot studies)
at 24 hours after catheterization. Oral treatment (by
gavage) with 8 mg/kg/d salicylic acid or intravenous
treatment with 8 mg/kg/d acetylsalicylic acid (Bayer
AG, Leverkusen, Germany) was initiated at 24 hours
after infection, over the next 72 hours. This dose was
previously established (8) to exert maximal antimicro-
bial effects against S. aureus in this model. At 96 hours
after infection, animals were euthanized with a rapid
intravenous injection of 100 mg/kg sodium pentobar-
bital (Abbott Laboratories, Chicago, Illinois, USA).
During autopsy, vegetations and kidneys were removed
to determine vegetation weights, as well as bacterial
densities in vegetations and kidney lesions (8). In addi-
tion, vegetations were processed for in vivo fluores-
cence microscopy as previously described (22). All rab-
bits were treated in accordance with institutional and
US Public Health Service guidelines for the humane
care and treatment of animals.
Statistics. For in vitro experi-
ments, the one-way Kruskal-Wallis
ANOVA test and the Dunn’s post
hoc comparison were used to com-
pare data sets generated for S.
aureus cells precultured in salicylic
acid (30 or 50 µg/ml) with those
for untreated control cells. When
control cells were compared with
cells precultured in a single dose of
salicylic acid, the two-sided Mann-
Whitney U test was used. For in
vivo experiments, the two-sided
Mann-Whitney U test was used to
compare data sets generated in sal-
icylic acid–treated and untreated
animals. A P value ≤ 0.05 was con-
sidered significant.
Results
In vitro effect of salicylic acid on S. aureus virulence phenotypes
upregulated by sarA. Parental S. aureus cells precultured in
the presence of salicylic acid demonstrated a substantial,
dose-dependent reduction in binding to both fibronectin
and fibrinogen, at two clinically achievable serum con-
centrations (Table 2). The mitigating effects of salicylic
acid on S. aureus binding to these matrix proteins were vir-
tually eliminated when the organism was pre-exposed to
sodium azide, an inhibitor of oxidative phosphoryla-
tion (data not shown); this emphasized the require-
ment for an energy- dependent process in viable bacte-
ria to fully execute this salicylic acid–mediated effect.
Similar to the extent of binding, the extents of hemolysis
and thrombolysis, presumably mediated by α-hemolysin
in supernatants obtained from cells precultured in the
presence of salicylic acid, were significantly less than
observed with control cells. The extent of mitigation of
matrix protein binding and target cell cytolysis was very
similar between clinical and laboratory strains.
The in vitro hemolytic, thrombolytic (platelet lysis),
and matrix protein–binding assays were repeated with
two other clinically available NSAIDs, aspirin (the par-
ent compound of salicylic acid) and indomethacin. Nei-
ther of these agents yielded any substantial impact on
the cytolytic or matrix-binding phenotypes in parental
strains RN6390, COL, or Newman (data not shown).
Thus, there was a relative specificity of salicylic acid as
compared with several clinically used NSAIDs in regard
to the above impacts on the S. aureus phenotypes exam-
ined. More importantly, these data substantiated the
requirement of the conversion of acetylsalicylic acid to
salicylic acid for its in vitro antimicrobial properties.
In vitro effect of salicylic acid on S. aureus phenotypic and
genotypic parameters downregulated by sarA. The downreg-
ulation in the expression of fibronectin-binding proteins
and α-hemolysin due to salicylic acid is consistent with
a downregulation in SarA-mediated effects. To assess
other phenotypes that might be upregulated in S. aureus
as a result of diminished SarA expression, we examined
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Table 2
Effect of salicylic acid on fibronectin and fibrinogen binding, hemolysis, and thrombolysis
of laboratory S. aureus strains and clinical S. aureus isolates
Laboratory isolates Clinical isolates
SAL, 30 µg/ml SAL, 50 µg/ml SAL, 30 µg/ml SAL, 50 µg/ml
Fibronectin binding –35.9% ± 6.5%A –54.5% ± 5.1%B –28.9% ± 3.5%B –51.4% ± 2.0%B
Fibrinogen binding –35.4% ± 5.2%A –55.1% ± 4.9%B –32.4% ± 2.1%B –53.4% ± 2.9%B
Hemolysis –48% ± 4%B –62% ± 5%B –33% ± 13%A –54% ± 12%B
Thrombolysis –32% ± 4%A –45% ± 2%B –30% ± 6%A –48% ± 9%B
Numbers listed in the table indicate the mean reduction (± SD) as compared with controls (S. aureus
precultured in plain medium) used as the standard (i.e., 100%). Binding of S. aureus control cells (lab-
oratory or clinical isolates) to fibrinogen or fibronectin ranged from 7.1% to 10.2% of the inoculum.
Hemolytic and thrombolytic activity of S. aureus control cells ranged from 550 to 800 hemolytic units
and from 56% to 84%, respectively. The reductions in matrix protein binding and lysis represent com-
posite pooled data derived from the laboratory S. aureus strains RN6390, COL, Newman, and
ISP479C, and the clinical S. aureus isolates MRSA 67-0, 6850, Duke 28, Duke 153, and Duke 237.
SAL, salicylic acid. AP < 0.002, BP < 0.001.
protease and lipase activities. Protease and lipase activi-
ties were elevated in supernatants from parental S. aureus
strains exposed to salicylic acid: protease activity was
increased fivefold (P < 0.0001) and lipase activity was
increased 2.6-fold (P < 0.0001) in supernatants from sal-
icylic acid–treated cells versus untreated controls. The
salicylic acid–induced increase of protease activity was
blunted in cells precultured in the presence of the glob-
al protease inhibitor α2-macroglobulin. However, 50
µg/ml salicylic acid caused similar and significant reduc-
tions in fibronectin binding of the above parental strains
in the presence or absence of pre-exposure to α2-macro-
globulin (45.7% ± 4.2% vs. 53.9% ± 5.5% reductions,
respectively; P < 0.0001). These findings provide evidence
that the salicylic acid–induced suppression of the S.
aureus fibronectin-binding phenotype is not principally
related to an increase in protease secretion that leads to
adhesin inactivation (12).
A mean increase of 17.6% ± 3.9% in protein A levels
versus untreated controls was observed in parental S.
aureus strains exposed to 50 µg/ml salicylic acid. In par-
allel, a corresponding twofold increase in spa promoter
expression was noted in salicylic acid–treated cells as
compared with untreated controls, suggesting a sali-
cylic acid–mediated impact on the structural gene
and/or the respective regulator gene.
The role of sarA and sigB in salicylic acid–mediated modifi-
cations of S. aureus phenotypes. In sarA mutants of strain
RN6390 and its isogenic rsbU-repaired derivative
SH1000, intrinsic binding to fibrinogen and fibronectin
was reduced when compared with that in the corre-
sponding parental strains (fibrinogen, –52.7% ± 2.3%;
fibronectin, –54.2% ± 2.5%). Similarly, in these same sarA
mutants hemolysis and thrombolysis were reduced by
55% ± 5% and 57% ± 5%, respectively, when compared
with the parental strains. No significant reductions of
matrix protein binding and cytolytic profiles were
observed when the sarA mutants were pre-exposed to
salicylic acid (Table 3). These findings confirmed the
key importance of sarA in regulating staphylococcal
matrix protein binding and cytolysis gene products and
suggested a pivotal role for sarA in mediating the impact
of salicylic acid on S. aureus virulence phenotypes.
In the sigB knockouts of strains RN6390 and COL,
intrinsic binding to fibrinogen and fibronectin was
increased when compared with that in the respective
parental strains (fibrinogen, 19.4% ± 3.1%; fibronectin,
22.7% ± 2.6%). Hemolysis and thrombolysis in these
sigB knockouts were increased by 14.6% ± 5.7% and
17.5% ± 4.4%, respectively, when compared with those
in the parental strains. Salicylic acid–mediated reduc-
tions in matrix protein binding, hemolysis, and throm-
bolysis observed in these parental strains were mitigat-
ed in the respective sigB knockouts (Table 3). Moreover,
no impact of salicylic acid on protease-activity or lipase-
activity profiles or cell wall protein A production was
detectable in the sigB knockout of RN6390. These phe-
notypic response parameters were restored to parental
levels with complementation of sigB in the RN6390
background. Notably, salicylic acid caused similar
extents of reduction in matrix protein binding and
cytolytic profiles in parental strain RN6390 and its
rsbU-repaired derivative SH1000 (Table 3).
In summary, the above observations suggest that in
parental S. aureus strains, salicylic acid suppresses exotox-
in production and matrix protein binding, while enhanc-
ing exoenzyme (e.g., protease and lipase) and protein A
production. The presence of an intact sarA locus and the
sigB stress operon (with or without a functional rsbU locus)
appears to be a prerequisite in this context. Therefore, this
composite phenotype is consistent with suppression of
sarA expression following sigB activation in either an rsbU-
dependent or an rsbU-independent manner (13–16).
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Table 3
Effect of 50 µg/ml salicylic acid on fibronectin and fibrinogen binding, hemolysis, and thrombolysis of the S. aureus strains listed
RN6390 RN6390 SH1000 rsbU+ SH1000 RN6390 RN6390 COL COL sigB
parent sarA– mutant derivative sarA– mutant sigB mutant sigB compl. parent mutant
Fibronectin binding –54.6 ± 7.3A –14.38 ± 3.4 –40.8 ± 3.6A –7.2 ± 0.4 –8.6 ± 2.6 –49.7 ± 6.2A –53.6 ± 6.1A –5.6 ± 0.7
Fibrinogen binding –51.6 ± 5.2A –11.16 ± 4.1 –45.6 ± 3.7A –12.6 ± 0.8 –7.1 ± 2.2 –51.2 ± 6.5A –51.2 ± 6.9A –6.6 ± 1.0
Hemolysis –64 ± 8A –9 ± 2 –51 ± 5A –10 ± 14 –4 ± 1 –56 ± 9A –67 ± 5A –3 ± 1
Thrombolysis –58 ± 7A –13 ± 2 –45 ± 6A –6 ± 4 –3 ± 1 –53 ± 6A –49 ± 4A –2 ± 1
The background of each strain is indicated next to the mutant type. Numbers indicate the percent mean reduction (± SD) as compared with controls (S. aureus
precultured in plain medium). Compl., complemented. AP < 0.003.
Figure 1
Western blot for detection of α-hemolysin. An immunoblot of cul-
ture supernatants of the indicated S. aureus strains precultured in the
absence (controls) or presence of 30 and 50 µg/ml salicylic acid to
the early stationary phase (18 hours) was probed for α-hemolysin.
Affinity-purified rabbit polyclonal anti–α-hemolysin IgG was used as
the primary antibody. SAL, salicylic acid.
α-Hemolysin production. Paralleling the hemolytic and
thrombolytic data sets above, α-hemolysin was detect-
ed by immunoblots in supernatants of parental S.
aureus strains grown in the absence of salicylic acid but
was substantially diminished in the presence of salicylic
acid (Figure 1). Immunoblots of extracellular proteins
derived from supernatants of postexponential-phase
cultures of the RN6390 parent, its sigB mutant, and its
sigB-complemented variant grown in salicylic acid dis-
closed a substantial reduction in α-hemolysin produc-
tion in the parental and sigB-complemented strains, as
compared with little impact on α-hemolysin produc-
tion in the sigB deletion mutant (Figure 2). These data,
combined with the phenotypic findings above, clearly
support the notion that the sigB operon is pivotal in
mediating the antimicrobial effects of salicylic acid in
vitro in the context of cytolysis.
Salicylic acid–induced impacts on hla, fnbA, and fnbB pro-
moter expression in vitro. In parental strain RN6390, fluo-
rometric analyses revealed a 2.9-fold and a 2.1-fold
decrease, respectively, in fnbA and fnbB promoter expres-
sion in cells treated with 50 µg/ml salicylic acid, as com-
pared with untreated controls. Similarly, there was a 3.3-
fold reduction in hla promoter expression in salicylic
acid–treated cells, compared with untreated control cells.
These data demonstrate that the mitigating effects of sal-
icylic acid on staphylococcal fibronectin binding and on
α-hemolysin production were correlated with reduced
transcription of the relevant gene promoters in S. aureus.
Salicylic acid–induced impacts on sarA and agr promoter
expression and sigB gene expression in vitro. By fluoromet-
ric analysis, treatment of S. aureus RN6390 with 50
µg/ml salicylic acid caused (a) a 2.3-fold reduction in
the expression of the sarA P1 promoter, the strongest
promoter within the triple-sarA-promoter system; (b)
a 1.8-fold reduction in the native triple-sarA-promoter
complex (i.e., sarA P2-P3-P1); and (c) a 2.0-fold and a
2.2-fold reduction in agr RNAII and agr RNAIII pro-
moter expression, respectively, as compared with those
in untreated controls.
With respect to the sarA operon, we independently con-
firmed the above fluorometric data by both flow cytom-
etry and Northern analysis. There are three promoters
(P2, P3, and P1) upstream of the sarA coding region, with
the proximal P1 promoter being the strongest. Flow
cytometry revealed a 2.5-fold decrease in sarA P1 pro-
moter expression in the presence of salicylic acid, where-
as the activity of the middle sarA promoter, P3, which is
sigB-dependent, was twofold higher in salicylic acid–treat-
ed than in untreated cells (Figure 3a). Consistent with
the flow cytometry data sets, Northern analysis of
strains RN6390 (Figure 3b) and Newman (not shown) 
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Figure 2
Western blot for detection of α-hemolysin in isogenic strain RN6390,
its sigB transposon mutant, and its sigB-complemented variant. An
immunoblot of stationary-phase culture supernatants (18 hours) of
the indicated strains precultured in the absence (controls) or pres-
ence of 50 µg/ml salicylic acid is shown. Affinity-purified polyclonal
rabbit anti–α-hemolysin IgG served as the primary antibody.
Figure 3
(a) Flow cytometric analysis of salicylic acid–induced effects on sar-gfpuvr constructs. In S. aureus RN6390, flow cytometry demonstrated a
2.5-fold attenuation of P1-initiated sarA promoter activity (left) and a 1.8-fold increase of P3-initiated sarA promoter activity (right) in cul-
tures pre-exposed to salicylic acid (50 µg/ml) as compared with expression in plain medium. (b) Effect of salicylic acid on sar promoter tran-
scription in S. aureus. Northern analysis revealed that in S. aureus RN6390 cells precultured in the presence of 50 µg/ml salicylic acid, P1-ini-
tiated sarA transcription was suppressed, whereas P3-initiated sarA transcription (corresponds to sarC) was enhanced in the late log phase
and postexponential phase, as compared with cells precultured in plain medium. The P2-initiated sarA transcription level (corresponds to
sarB) was too weak to define the impact of salicylic acid on this locus.
demonstrated that the sarA P3 transcript level was
increased in cells pre-exposed to salicylic acid when com-
pared with untreated cells, while the sarA P1 transcript
level was decreased compared with that in untreated cells.
The upregulation of the sarA P3 transcript in
response to salicylic acid further suggested a salicylic
acid–induced upregulation of sigB. Therefore, we used
fluorometry to analyze the impact of salicylic acid on
expression of a major sigB-dependent promoter, asp23,
in three S. aureus strains with two distinct back-
grounds: (a) RN6390, carrying a natural rsbU deletion
within the sigB operon; (b) SH1000, the functional
rsbU derivative of RN6390; and (c) FDA486, carrying
an intact sigB operon. In these strains, salicylic acid
caused a 1.5- to 1.9-fold increase in asp23 promoter
expression as compared with that in untreated cells.
Collectively, these data demonstrate a net salicylic
acid–mediated downmodulation of both the sarA and
the agr operons, associated with an upregulation of
sigB, which occurred in both the presence and the
absence of an intact rsbU locus within the sigB operon.
Expression of SarA protein in S. aureus strain SH1000
upon exposure to salicylic acid. To determine whether a
change in SarA protein level occurred in strain SH1000
(with an intact sigB locus) when it was exposed to sali-
cylic acid, we probed an immunoblot containing
equivalent amounts of early stationary-phase cell
extracts of strain SH1000, precultured in the presence
and absence of salicylic acid, with an anti-SarA mAb.
At 50 µg of cellular proteins, there was a 10% reduction
in SarA protein levels in cells precultured in salicylic
acid at 50 µg/ml (516 vs. 576 densitometric units in
treated and untreated cells, respectively).
The role of the sarA locus in salicylic acid–mediated effects in
vivo. Aortic-catheterized rabbits were challenged intra-
venously with either parental strain RN6390 or its iso-
genic sarA knockout mutant. Rabbits treated with 8
mg/kg/d salicylic acid and infected with parental strain
RN6390 demonstrated significantly smaller vegeta-
tions and lower bacterial densities in vegetations and
kidney lesions than did their respective untreated con-
trols; these effects were substantially blunted in sali-
cylic acid–treated rabbits challenged with the sarA
knockout mutant (Table 4). Thus, the sarA locus plays
a predominant role in mediating the in vivo effects of
salicylic acid, paralleling the in vitro data above.
To further substantiate the in vivo downmodulatory
impact of salicylic acid on sarA expression, aortic-
catheterized rabbits and infected with the S. aureus
RN6390 sarA P1:gfpuvr construct either went untreated
or received 8 mg/kg/d aspirin intravenously. While bac-
terial cells in vegetations from control animals demon-
strated a high level of in situ GFP fluorescence, cells
from aspirin-treated rabbits showed a substantial reduc-
tion in GFP fluorescence, indicative of reduced sarA P1
expression in the presence of salicylic acid in vivo 
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Table 4
Effect of salicylic acid on microbial proliferation and hematogenous dissemination in rabbits with infective endocarditis challenged with
parental strain RN6390 or its sarA mutant
Strains Number of animalsA Vegetation weight Vegetation bacterial density Renal bacterial density 
(g) (log10 CFUs/g tissue) (log10 CFUs/g tissue)
Control Treatment Control Treatment Control Treatment Control Treatment
RN6390 8 8 0.12 ± 0.01 0.07 ± 0.01B 8.32 ± 0.93 6.19 ± 0.92B 8.41 ± 0.88 6.19 ± 0.89B
sarA mutant 7 8 0.12 ± 0.01 0.11 ± 0.02 7.56 ± 0.63 7.28 ± 1.43 7.49 ± 0.65 7.34 ± 1.37
In vivo plasma levels of salicylic acid were evaluated in the treatment groups by an immunoassay and were 51 ± 2.9 µg/ml (47–55 µg/ml). AMean mortality
rate 13.9% (range 11.1–22.2%). Mean mortality rate without significant differences between groups. BP < 0.007 vs. control.
Figure 4
Fluorescence analysis of aspirin-induced effects on sarA P1:gfpuvr con-
structs in vivo. Vegetative lesions were removed from rabbits with
infective endocarditis 24 hours after they received no treatment (con-
trols) or a single intravenous dose of 8 mg/kg aspirin, and fluores-
cence microscopy was conducted on sarA P1:gfpuvr constructs within
the lesions. In vegetations from control rabbits, bright green fluores-
cence (a) can be clearly detected as originating from the respective
cells shown in the adjacent section stained with Giemsa (b). In com-
parison, the fluorescence intensities of individual bacterial cells found
in Giemsa-stained vegetation sections of aspirin-treated rabbits (d)
show a marked reduction in fluorescence (c, arrowheads), even at the
highest immunofluorescent microscopy gain (magnification ×350).
(Figure 4). These observations were quantitatively con-
firmed via flow cytometry by the substantially reduced
sarA P1 promoter–driven GFP expression among 10,000
staphylococcal cells isolated from aspirin-treated versus
control vegetations (data not shown).
The role of the sigB operon in salicylic acid–mediated effects
in vivo. In rabbits catheterized in the aorta and infected
with parental S. aureus strain RN6390 or COL or the
RN6390 sigB-complemented mutant, salicylic acid ther-
apy yielded significant reductions in vegetation weight,
as well as in vegetation and kidney bacterial densities,
as compared with their respective untreated controls.
In contrast, in rabbits infected with the sigB deletion
mutants of either RN6390 or COL, salicylic acid treat-
ment did not yield any significant effects on these
parameters (Table 5). The salutary effects of salicylic
acid therapy in animals infected with parental strain
RN6390 were closely paralleled in salicylic acid–treat-
ed animals infected with its rsbU-repaired derivative
SH1000 (Table 5). Taken together, these data further
confirmed the integral role of the sigB operon in medi-
ating the antimicrobial effects of salicylic acid in vivo.
Discussion
Over the past decade, a number of investigations have
demonstrated that acetylsalicylic acid and/or its pre-
dominant metabolite, salicylic acid, exhibit definable
impacts both in vitro and in vivo on microbial virulence
phenotypes. The following effects have been noted:
reduction of adhesion to relevant biomatrices (29),
reduction of capsule production (30), mitigation of
biofilm formation (31), and diminution of vegetation
growth, intravegetation bacterial proliferation, and
hematogenous dissemination in experimental infective
endocarditis (32). Salicylic acid also has been shown to
upregulate the translation of specific gene loci, includ-
ing multiple antibiotic-resistance loci (33); to induce
cytoplasmic proteins (34); and to increase quinolone
resistance (35). We recently studied the potential
antimicrobial mechanisms of aspirin in the infective
endocarditis model (8) and demonstrated that salicylic
acid was the principal mediator of these antimicrobial
effects in vivo. The present study was designed to fur-
ther characterize the in vitro and in vivo impact of sal-
icylic acid, particularly focusing on potential microbial
genetic pathways involved in these effects, in the con-
text of experimental infective endocarditis.
We demonstrated that, at levels achievable in human
serum (11), salicylic acid mitigated two distinct viru-
lence phenotypes that are of key relevance in the patho-
genesis of experimental infective endocarditis: matrix
protein binding (i.e., to fibrinogen and fibronectin) and
α-hemolysin activity. These effects were specifically
associated with salicylic acid–mediated reductions in
the expression of the respective structural genes (i.e.,
fnbA, fnbB, and hla). Thus, for the fibronectin-binding
phenotype, salicylic acid–mediated reduction in bind-
ing can clearly be linked to a negative impact on the
fnbA and/or fnbB genes. However, the reduction in over-
all binding of S. aureus to fibrinogen likely relates to a
multifactorial impact of salicylic acid. For example, the
expression of ClfA (a principal fibrinogen adhesin) can
be upregulated by sigB (36). Therefore, salicylic acid
could potentially either reduce or increase ClfA expres-
sion, depending on the growth phase. Moreover, the
fibronectin-binding adhesin FnbA can mediate binding
to fibrinogen as well as fibronectin (37). Finally, there
are other fibrinogen-binding adhesins (e.g., Coa, ClfB)
that could also be influenced by salicylic acid treatment.
Therefore, the net mitigating effect of salicylic acid on
S. aureus binding to fibrinogen is likely to reflect the
composite impact on sarA, fnbA, and/or fnbB expression.
In addition to the suppression of matrix protein
binding and cytolytic profiles, enhanced exoenzyme
and protein A production was observed in the presence
of salicylic acid. These pleiotropic phenotypic findings
raised the likelihood that salicylic acid executed its
antimicrobial effects through one or more global reg-
ulatory networks rather than a decrease in general gene
transcription. We focused our investigations on three
global regulons, sarA, agr, and sigB, since they have each
been shown to impact one or more of the above phe-
notypes and have been implicated in in vivo virulence,
including in infective endocarditis (19, 38).
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Table 5
Effect of salicylic acid on microbial proliferation in vegetative lesions and hematogenous dissemination to kidneys of rabbits with experi-
mental endocarditis due to the S. aureus strains listed
Strains Number of animalsA Vegetation weight Vegetation bacterial density Renal bacterial density
(g) (log10 CFUs/g tissue) (log10 CFUs/g tissue)
Control Treatment Control Treatment Control Treatment Control Treatment
RN6390 7 6 0.12 ± 0.01 0.07 ± 0.01B 8.42 ± 0.79 6.45 ± 0.91C 8.05 ± 0.89 6.38 ± 0.9C
sigB mutant (RN6390) 6 6 0.13 ± 0.01 0.12 ± 0.01 8.71 ± 0.89 8.37 ± 0.99 8.47 ± 0.79 8.17 ± 0.94
sigB complemented (RN6390) 6 6 0.11 ± 0.01 0.06 ± 0.01B 7.97 ± 0.78 5.98 ± 0.66C 7.95 ± 0.86 6.09 ± 0.96C
SH1000 5 5 0.25 ± 0.07 0.18 ± 0.06 6.54 ± 0.58 4.83 ± 0.7E 5.39 ± 1.14 3.43 ± 0.8E
COL 7 7 0.17 ± 0.09 0.05 ± 0.02B 8.27 ± 0.92 5.1 ± 0.77C 6.62 ± 1.02 4.08 ± 0.82D
sigB mutant (COL) 6 7 0.13 ± 0.04 0.12 ± 0.06 7.24 ± 0.61 7.2 ± 0.68 6.44 ± 0.79 6.36 ± 1.25
Each respective background strain is indicated next to the mutant. In vivo plasma levels of salicylic acid were evaluated in the treatment groups by an immunoas-
say and were 49 ± 2.4 µg/ml (46–57 µg/ml). AMean mortality rate 8.4% (range 0–14.3%). Mean mortality rate without significant differences between groups.
BP < 0.002 vs. control group; CP < 0.01 vs. control group; DP < 0.03 vs. control group; EP < 0.05 vs. control group.
In S. aureus, the global regulatory element sarA upreg-
ulates the expression of a number of matrix adhesin
genes (e.g., fnbA) and exotoxin genes (e.g., hla), while
downregulating certain enzyme genes (e.g., serine pro-
tease [sppa] and lipase [geh]) and protein A production
(spa) (13, 14). The sarA locus is also involved in maxi-
mizing activation of the agr operon, an additional key
global regulatory locus of S. aureus, which is particu-
larly involved in α-hemolysin production (e.g., via hla)
(39, 40). Transcriptional analysis indicates that the sarA
locus is composed of three overlapping transcripts, des-
ignated sarA P1, sarA P3, and sarA P2 (41), all encoding
the 14.5-kDa SarA protein, the major effector molecule
of this locus. Recognizing that differential sarA pro-
moter activation may modulate SarA expression, we
explored the effects of salicylic acid on both the indi-
vidual sarA promoters and the entire sarA operon, and
also on the promoters of agr RNAII and RNAIII. North-
ern analysis, fluorometry, and flow cytometry studies
demonstrated a salicylic acid–induced suppression of
the sarA P1 promoter and of expression of the intact
sarA P2-P3-P1 promoter complex, with a concomitant
upregulation of the sarA P3 promoter. As the sarA P1
promoter is the strongest promoter of the sarA locus,
this salicylic acid–mediated diminution in its activa-
tion correlates well with mitigation of sarA-dependent
phenotypes (e.g., adhesin and α-hemolysin functions).
Our immunoblot studies disclosed a 10% salicylic
acid–mediated reduction in SarA protein expression,
consistent with the key role of the sarA locus in this
context. The salicylic acid–mediated decrease in SarA
protein levels was smaller than the reduction in sarA P1
promoter expression, by transcriptional fusion analy-
ses. These data are concordant with the relative insen-
sitivity of the immunoblot to detect modest differences
in gene expression.
Additionally, our in vivo data underscored the sig-
nificance of sarA in mediating salicylic acid–induced
antivirulence effects. Importantly, we showed a sup-
pression of sarA P1 promoter activity in animals with
infective endocarditis treated with aspirin. Moreover,
treatment of animals with salicylic acid reduced sev-
eral key parameters of disease severity (e.g., vegeta-
tion weights, and vegetation and renal bacterial den-
sities) in experimental infective endocarditis caused
by the parental strain, but not in that caused by an
isogenic sarA knockout construct. The inverse rela-
tionship between the sarA P1 and the sarA P3 pro-
moter effects in the presence of salicylic acid (i.e.,
decreased sarA P1 transcription and increased sarA P3
transcription) fits the current paradigm of sarA reg-
ulation. Thus, activation of the otherwise quiescent
sarA P3 promoter upstream may interfere with acti-
vation of the proximal but stronger sarA P1 promot-
er. This mechanism is thought to occur either by pro-
moter occlusion or by the binding of a repressor
protein between the sarA P1 and the sarA P3 promot-
er (28, 41). These findings provided important clues
that the overall antistaphylococcal effect of salicylic
acid is likely executed via additional regulatory ele-
ments that upregulate the sarA P3 promoter (e.g.,
sigB) (15, 16). Although the above data clearly impli-
cate sarA in mediation of the salutary impacts of sal-
icylic acid in vivo, we cannot precisely quantify the
potential contributions of a large cadre of responsive
downstream structural genes in this context.
The salicylic acid–induced suppression of sarA was
accompanied by a reduction in agr RNAII and agr
RNAIII promoter expression. It has previously been
shown that SarA has binding specificity for the P2 and
P3 interpromoter region of agr, thereby activating
RNAII and RNAIII transcription (40). Therefore,
downregulation of the agr promoters might either
constitute a direct salicylic acid–induced effect on the
agr locus, or be indirectly mediated via suppression of
the sarA locus. Similarly, salicylic acid–mediated reduc-
tion in α-hemolysin production might be multimodal,
i.e., via suppression of agr-dependent or sarA-depend-
ent pathways, since the hla promoter is activated in
response to both signals (42).
It should be noted that S. aureus virulence parameters
in vitro (e.g., matrix protein adhesion and cytolysins)
were not completely suppressed by salicylic acid but
were reduced, in a drug concentration–dependent
manner, by a maximum of approximately 50%. This
finding correlates with the relative extents of sarA P1
and P2-P3-P1 promoter suppression, and concomitant
sarA P3 promoter activation by both Northern and flu-
orometric analyses. It should also be emphasized that,
in vivo, tissue bacterial densities were reduced by
approximately 1 log10 CFUs/g in untreated animals
infected with an S. aureus sarA mutant; in contrast, sal-
icylic acid treatment in animals infected with its sarA-
intact parent strain yielded approximately 2 log10 CFUs/g
decrease in tissue bacterial densities. These findings
suggest that sarA-independent and/or sarA-coregulat-
ed pathways are likely involved in salicylic acid–induced
suppression of in vivo and in vitro virulence parame-
ters. This notion is supported by: (a) the presence of at
least 16 two-component regulatory systems in S. aureus,
one or more of which may be responsive to salicylic acid
(43); (b) the burgeoning family of sarA homologs that
impact S. aureus virulence determinants (43); and (c) the
numerous (>100) sarA-regulated downstream genes in
S. aureus (44). It is therefore not surprising that regula-
tory pathways other than sarA and agr would be in-
volved in salicylic acid–induced impacts. Studies of the
potential effects of salicylic acid on candidate sarA
homologs are in progress in our laboratories. Finally,
mechanisms other than global regulatory elements —
for example, direct effects on downstream structural
genes and their encoded gene products — might con-
tribute to salicylic acid impacts on S. aureus virulence
and cannot be excluded.
Alternative σ factors have been shown to contribute
importantly to bacterial survival by regulating stress-
response genes in response to environmental stimuli
(e.g., pH, heat shock), growth phase–specific signals
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(e.g., the stationary phase of growth), and ATP-depri-
vation conditions (e.g., anaerobic growth) (45, 46). As
part of the RNA polymerase holoenzyme, alternative σ
factors in Gram-positive bacteria function to enable
the organism to transcribe genes that are activated in
response to stresses in hostile environments (e.g., low
pH of abscesses) (38). In S. aureus, the sigB operon has
been shown to participate in the transcriptional regu-
lation of sarA (15, 16, 28), principally via sigB-depend-
ent activation of the sarA P3 promoter. We confirmed
the salicylic acid–mediated activation of sarA P3 by two
independent in vitro assays, flow cytometry and
Northern analysis. In addition, enhancement of the
sigB operon was demonstrated fluorometrically by sal-
icylic acid–induced increases in the expression of the
sigB-dependent promoter asp23. Furthermore, the key
role of the sigB operon in executing the antivirulence
properties of salicylic acid was shown in two distinct
genetic background strains (RN6390 and COL). In
these strains, deletion of the sigB operon abrogated the
salicylic acid–mediated suppression of in vitro matrix
protein binding, α-hemolysin production, and in vivo
S. aureus virulence in infective endocarditis. The sali-
cylic acid–mediated mitigation of these phenotypes
was restored following sigB complementation.
Using current genetic paradigms for sigB, agr, and
sarA regulon interactions and their downstream effects
on major structural virulence genes, our data sets
would suggest the following pathway for salicylic
acid–mediated impacts: Salicylic acid activates the sigB
operon, which then stimulates the sigB-dependent sarA
P3 promoter. In turn, sarA P1 promoter expression is
repressed, leading to downmodulation of sarA and the
ensuing agr activation. These events would be expected
to repress sarA-upregulatable genes (e.g., fnbA, fnbB,
hla), derepress sarA-downregulatable exoenzyme (e.g.,
lipase and protease) and protein A genes (e.g., spa), and
repress agr-upregulatable genes (e.g., hla).
The sigB operon of S. aureus consists of four genes,
rsbU, rsbV, rsbW, and sigB (45). Studies in Bacillus sub-
tilis indicate that rsbU is involved predominantly in
acid stress, while rsbV may mediate sigB activation in
response to other environmental stressors (e.g.,
drugs) (47). The ability of salicylic acid to activate sigB
and its downstream sigB-dependent promoters, sarA
P3 and asp23, in strain RN6390 was somewhat sur-
prising, since this strain carries a natural 11-bp dele-
tion within rsbU, leading, in vitro, to a state in which
sigB is relatively deficient (but not absent) (45). How-
ever, a virtually identical degree of salicylic
acid–mediated sigB activation was found in SH1000,
the functional rsbU derivative of RN6390, and in
FDA486, a strain with an intact rsbU gene. Moreover,
salicylic acid exposure yielded similar mitigating
impacts on in vitro phenotypes and in vivo virulence
events in strain RN6390 and its rsbU-repaired variant
SH1000, as well as in strain COL, a genetically dis-
tinct strain with an intact rsbU locus. These observa-
tions emphasize that the effects of salicylic acid may
be mediated via an rsbU-independent pathway with-
in the sigB operon, and that such pathways may vary
between distinct strains.
With the current widespread problem of multian-
tibiotic resistance in S. aureus, development of new
therapeutic agents that can mitigate the activation of
bacterial virulence genes required for initiating and
propagating infections is considered a high priority. In
this respect, the use of aspirin and salicylic acid
appears to reduce staphylococcal virulence, rather
than inducing bactericidal activity. Provided that a
favorable safety profile is established in therapeutic tri-
als of systemic S. aureus infection, aspirin may have the
potential to be an effective adjunctive agent in the
treatment of serious hospital- or community-acquired
S. aureus infections.
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